Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244433 | 0.78 | TSHR (0.36) | — | |
| SCHEMBL2511727 | 0.77 | TRPM8 (0.38) | — | |
| SCHEMBL18245670 | 0.72 | TRPM8 (0.38) | — | |
| SCHEMBL29156036 | 0.72 | TRPM8 (0.38) | — | |
| SCHEMBL2355639 | 0.71 | GABBR2 (0.45) | GABBR2GABBR1GABRR1 | |
| Hydrochloric Acid SCHEMBL2407944 | 0.70 | GABBR2 (0.43) | GABBR2GABBR1GABRR1 | |
| SCHEMBL2409014 | 0.70 | GABBR2 (0.43) | GABBR2GABBR1GABRR1 | |
| SCHEMBL753508 | 0.69 | TSHR (0.33) | — | |
| SCHEMBL2407046 | 0.68 | CA1 (0.41) | — | |
| SCHEMBL6615334 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| US-8604232-B2 | Method for producing monoamino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213079-A1 | Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213078-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylnitriles and Use Thereof | AOC2, AOC3, DAO | GABBR2 1586/4885GABBR1 1827/4885GABRR1 2636/4885 |
| US-20110213079-A1 | Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof | DAO, HAO2, AOC1 | GABBR2 2363/4885GABBR1 2860/4885GABRR1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.